Latest Content

FDA Approves Imfinzi Therapy in Muscle Invasive Bladder Cancer

March 28th 2025, 9:11pm

By Ryan Scott

Article

The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in muscle invasive bladder cancer.

Life Goes On, Even With Breast Cancer

March 28th 2025, 8:00pm

By Laura Yeager

Article

I reflect on how cancer has brought out resilience and support in others, even as I struggled with my own battle, and wish others strength in their journeys.

Why Physical Therapy Should Begin at the Time of a Cancer Diagnosis

March 28th 2025, 7:11pm

By Leslie Waltke

Video

CURE spoke with Leslie Waltke about the importance of physical therapy during a cancer journey.

FDA Expands Pluvicto Indication in Prostate Cancer Subset

March 28th 2025, 5:13pm

By Spencer Feldman

Article

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with androgen receptor inhibitors.

SON-1010 Generates Safe Results in Advanced Sarcoma

March 28th 2025, 4:00pm

By Alex Biese

Article

A phase 1 trial has reported positive safety findings of SON-1010 among patients with advanced leiomyosarcoma (LMS) or liposarcoma (LPS).

Solnerstotug Demonstrates Early Efficacy in PD-L1 Resistant Tumors

March 28th 2025, 3:00pm

By Spencer Feldman

Article

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.

Childhood Cancer Survivors May Experience Sooner Aging-Related Disease

March 28th 2025, 1:00pm

By Alex Biese

Article

Researchers have found childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population.

Kidney Cancer Awareness Month Highlights Advocacy and Early Detection

March 27th 2025, 9:00pm

By Ryan Scott

Article

March is Kidney Cancer Awareness Month, highlighting the disease, early detection and and patient advocacy, with voices like Sid Sadler raising awareness.

Clinical Trial to Evaluate Opdivo, Opdualag in Glioblastoma

March 27th 2025, 8:53pm

By Georgina Long

Video

The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

Quadruplet Regimen Preferable to Triplets in Multiple Myeloma

March 27th 2025, 7:00pm

By Alex Biese

Article

Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.

Snow, A Wig, and Memories After My Breast Cancer Diagnosis

March 27th 2025, 5:00pm

By Bonnie Annis

Article

Cancer memories often sneak up on me when I least expect them to.

CAN-2409 Elicits Survival Responses In NSCLC

March 27th 2025, 4:00pm

By Alex Biese

Article

Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer.

Itolizumab Shows Long-Term Treatment Benefits in Acute GVHD

March 27th 2025, 3:00pm

By Ryan Scott

Article

Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant benefits in long-term outcomes.

Rina-S Generates Antitumor Activity in Heavily Pretreated Ovarian Cancer

March 27th 2025, 1:00pm

By Dr. Elizabeth K. Lee

Video

Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the phase 2 RAINFOL-01 study.

A VXM01 Vaccine Combination Generates Safe Responses in Glioblastoma

March 26th 2025, 9:00pm

By Ryan Scott

Article

Treatment with VXM01, an investigational vaccine, plus Bavencio demonstrated both safety and tolerability in patients with recurrent glioblastoma.